Experienced biotech CFO, Corporate Development and Board member (Anglo Saxon and Germanic Systems) as an entrepreneur, VC, and consultant. Unique experience in orchestrating life science related start ups, fund raising, deal modeling/negotiation, competitor and market analysis, technology assessment, due diligence and evaluating private and public sector opportunities.Currently actively involved in business plan preparation, identifying and working with potential launch customers and fund raising with two life science related companies. Consultant/Director Investor Relations OBN.As CFO with two biotech and a vc/pe firm recruited auditors/accountants and led preparation of audited financials (US, Irish, Netherlands, Belgium GAAP and IFRS).. Extensive experience in market and competitive analysis, strategic planning, fund raising, financial and deal modeling, cash flow forecasting, capital allocation and technology licensing agreements. Negotiated patent license (MIT) and patent option (Yale). Led due diligence on more than 50 investment opportunities, participated in purchase of two portfolios. Orchestrated business plans that raised more than $40 million in equity and grants for 4 biotech companies. Board positions include 2 biotech, 2 software, Irish BioIndustry Association. Unique experience evaluating new technology in commercial and military applications. Forty one years experience conducting industry sector analyses, due diligence, valuation, strategy formulation, competitor analysis, market analysis of commercial opportunities in key sectors and fostering entrepreneurship. At OTA played key role in the NAFTA debate. Experienced academic, and lecturer, for leading business schools, universities. and briefer of senior government officials. Winner of the 1998 EFMD Case Competition (European Management). BA magna cum laude Eisenhower College, MBA 2nd Year Honors, Harvard Business School, 2 Year MPA Harvard JFK School, Ph.D. King’s College, London.
Listed skills include Venture Capital, Due Diligence, Growth Capital, Principal Investing, and 22 others.
